Regeneron Pharmaceuticals - REGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $746.33
  • Forecasted Upside: 8.34 %
  • Number of Analysts: 20
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$688.87
▼ -2.95 (-0.43%)

This chart shows the closing price for REGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Regeneron Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REGN

Analyst Price Target is $746.33
▲ +8.34% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Regeneron Pharmaceuticals in the last 3 months. The average price target is $746.33, with a high forecast of $925.00 and a low forecast of $575.00. The average price target represents a 8.34% upside from the last price of $688.87.

This chart shows the closing price for REGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 20 investment analysts is to buy stock in Regeneron Pharmaceuticals. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 1 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 1 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 1 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$700.00 ➝ $750.00Low
9/16/2022Canaccord Genuity GroupBoost TargetBuy$700.00 ➝ $750.00Low
9/13/2022Piper SandlerBoost TargetOverweight$692.00 ➝ $775.00Low
9/12/2022GuggenheimBoost Target$740.00 ➝ $925.00Low
9/12/2022Wells Fargo & CompanyBoost TargetOverweight$735.00 ➝ $800.00Low
9/9/2022Truist FinancialBoost Target$718.00 ➝ $790.00Low
9/9/2022SVB LeerinkBoost TargetMarket Perform ➝ Market Perform$630.00 ➝ $756.00Low
9/9/2022BarclaysBoost TargetOverweight$735.00 ➝ $815.00Low
9/9/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$625.00 ➝ $851.00Low
9/8/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold$536.00 ➝ $675.00Low
8/9/2022CowenBoost Target$655.00Low
8/4/2022BMO Capital MarketsBoost TargetOutperform$757.00 ➝ $788.00Low
8/4/2022Morgan StanleyBoost TargetEqual Weight$619.00 ➝ $625.00Low
7/25/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$630.00Low
7/20/2022CowenBoost TargetMarket Perform$635.00 ➝ $645.00Low
7/20/2022CowenBoost Target$635.00 ➝ $645.00Low
7/15/2022Morgan StanleyBoost TargetEqual Weight$610.00 ➝ $619.00Low
7/12/2022Cantor FitzgeraldInitiated CoverageNeutral$625.00N/A
6/20/2022Evercore ISISet Target$635.00Low
6/17/2022Jefferies Financial GroupDowngradeSell$536.00Low
6/6/2022Jefferies Financial GroupInitiated CoverageUnderperform$536.00High
6/3/2022Wells Fargo & CompanyLower TargetOverweight$750.00 ➝ $735.00Low
6/3/2022Morgan StanleyLower TargetEqual Weight$620.00 ➝ $610.00Low
5/31/2022ArgusBoost TargetBuy$680.00 ➝ $760.00High
5/23/2022SVB LeerinkInitiated CoverageOutperform$738.00Medium
4/20/2022CowenBoost Target$640.00 ➝ $645.00Low
4/20/2022CowenBoost Target$640.00 ➝ $645.00Low
4/12/2022Morgan StanleyBoost TargetEqual Weight$605.00 ➝ $632.00Low
4/12/2022BarclaysBoost TargetOverweight$700.00 ➝ $745.00Medium
2/11/2022BMO Capital MarketsReiterated RatingBuy$780.00High
2/8/2022Truist FinancialLower TargetBuy$754.00 ➝ $728.00Low
2/8/2022OppenheimerLower TargetOutperform$825.00 ➝ $775.00Low
2/7/2022Morgan StanleyBoost TargetEqual Weight$585.00 ➝ $605.00Low
2/4/2022BMO Capital MarketsReiterated RatingBuy$780.00Low
2/4/2022Piper SandlerBoost TargetOverweight ➝ Overweight$690.00 ➝ $692.00Low
1/31/2022Truist FinancialLower TargetBuy$756.00 ➝ $754.00Medium
1/18/2022Morgan StanleyLower TargetEqual Weight$617.00 ➝ $585.00High
1/5/2022Bank of AmericaDowngradeNeutral ➝ Underperform$675.00 ➝ $575.00High
1/3/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$660.00High
12/15/2021Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$660.00Low
12/14/2021SVB LeerinkReiterated RatingBuyMedium
12/13/2021HC WainwrightReiterated RatingBuyHigh
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$750.00High
12/7/2021CowenInitiated CoverageMarket Perform$625.00Low
12/6/2021The Goldman Sachs GroupInitiated CoverageBuy$824.00Medium
11/19/2021BMO Capital MarketsInitiated CoverageOutperform$780.00Low
11/10/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$700.00 ➝ $760.00Medium
11/5/2021SVB LeerinkBoost TargetOutperform$798.00 ➝ $850.00Medium
11/5/2021Morgan StanleyBoost TargetEqual Weight$571.00 ➝ $617.00Low
11/5/2021BenchmarkDowngradeBuy ➝ HoldHigh
11/5/2021HC WainwrightBoost TargetBuy$842.00 ➝ $844.00Medium
10/26/2021SVB LeerinkBoost TargetOutperform$785.00 ➝ $798.00Medium
10/22/2021HC WainwrightBoost TargetBuy$831.00 ➝ $842.00Low
10/12/2021Morgan StanleyLower TargetEqual Weight$606.00 ➝ $571.00Low
10/4/2021HC WainwrightReiterated RatingBuy$831.00High
9/21/2021BMO Capital MarketsBoost TargetOutperform$669.00 ➝ $706.00Low
9/15/2021Piper SandlerBoost TargetOverweight$675.00 ➝ $690.00Low
9/15/2021Cantor FitzgeraldBoost TargetOverweight$670.00 ➝ $700.00Medium
9/15/2021HC WainwrightBoost TargetBuy$787.00 ➝ $831.00Medium
9/9/2021UBS GroupInitiated CoverageBuy$763.00High
9/7/2021Morgan StanleyBoost TargetEqual Weight$576.00 ➝ $606.00Low
8/23/2021BenchmarkBoost TargetBuy$636.00 ➝ $727.00Low
8/20/2021HC WainwrightReiterated RatingBuy$787.00Low
8/6/2021BarclaysBoost TargetOverweight$675.00 ➝ $705.00Medium
8/6/2021SVB LeerinkBoost TargetOutperform$641.00 ➝ $725.00High
8/6/2021BMO Capital MarketsBoost TargetOutperform$625.00 ➝ $669.00High
8/6/2021OppenheimerBoost TargetOutperform$725.00 ➝ $825.00Medium
8/5/2021Piper SandlerBoost TargetOverweight$650.00 ➝ $675.00High
8/2/2021HC WainwrightBoost TargetBuy$729.00 ➝ $741.00Low
7/23/2021Royal Bank of CanadaBoost TargetSector Perform$629.00 ➝ $679.00Low
7/8/2021BenchmarkBoost TargetBuy$590.00 ➝ $636.00Low
6/29/2021HC WainwrightInitiated CoverageBuy$703.00Low
5/7/2021SVB LeerinkLower TargetOutperform$657.00 ➝ $641.00Low
5/7/2021Morgan StanleyBoost TargetEqual Weight$477.00 ➝ $495.00Low
4/19/2021Morgan StanleyLower TargetEqual Weight$525.00 ➝ $477.00Low
4/13/2021Robert W. BairdReiterated RatingHoldLow
3/26/2021SVB LeerinkBoost TargetOutperform$655.00 ➝ $657.00High
2/23/2021Credit Suisse GroupBoost TargetOutperform$753.00 ➝ $760.00High
2/16/2021Cantor FitzgeraldLower TargetOverweight$696.00 ➝ $656.00Low
2/8/2021Morgan StanleyLower TargetEqual Weight$553.00 ➝ $525.00Medium
2/8/2021Credit Suisse GroupLower TargetOutperform$758.00 ➝ $753.00Medium
2/8/2021CowenLower TargetOutperform$684.00 ➝ $565.00High
2/8/2021SVB LeerinkBoost TargetOutperform$623.00 ➝ $640.00High
1/25/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$630.00Medium
1/19/2021Morgan StanleyBoost TargetEqual Weight$527.00 ➝ $553.00Low
1/14/2021Smith Barney CitigroupBoost Target$575.00 ➝ $584.00Low
1/13/2021BenchmarkUpgradeHold ➝ Buy$590.00Medium
1/8/2021FIXUpgradeNeutral ➝ Buy$635.00 ➝ $575.00Medium
12/16/2020Morgan StanleyLower TargetEqual Weight$602.00 ➝ $527.00Low
12/16/2020Credit Suisse GroupLower TargetOutperform$737.00 ➝ $736.00Medium
11/9/2020Morgan StanleyLower TargetEqual Weight$609.00 ➝ $602.00High
11/6/2020Truist FinancialBoost Target$750.00 ➝ $770.00Low
11/6/2020Credit Suisse GroupLower TargetOutperform$745.00 ➝ $737.00Low
11/6/2020SVB LeerinkBoost TargetOutperform$650.00 ➝ $653.00Low
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$626.00 ➝ $630.00Low
10/13/2020Morgan StanleyLower TargetEqual Weight$611.00 ➝ $609.00Low
10/6/2020SVB LeerinkBoost TargetOutperform$629.00 ➝ $650.00High
10/5/2020Cantor FitzgeraldUpgradeNeutral ➝ Overweight$690.00High
10/1/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
8/20/2020BenchmarkDowngradeBuy ➝ HoldHigh
8/7/2020Credit Suisse GroupBoost TargetOutperform$716.00 ➝ $725.00Low
8/6/2020BarclaysBoost Target$615.00 ➝ $675.00Low
8/6/2020Morgan StanleyLower TargetEqual Weight$619.00 ➝ $611.00Low
8/6/2020OppenheimerBoost TargetOutperform$675.00 ➝ $725.00Low
8/6/2020CitigroupBoost TargetNeutral$585.00 ➝ $635.00Low
8/6/2020BMO Capital MarketsBoost TargetOutperform$525.00 ➝ $626.00Low
8/5/2020The Goldman Sachs GroupBoost Target$700.00 ➝ $800.00Low
8/5/2020Piper SandlerBoost TargetOverweight$630.00 ➝ $675.00High
7/20/2020Credit Suisse GroupBoost TargetOutperform$700.00 ➝ $716.00High
7/15/2020Morgan StanleyBoost TargetEqual Weight$555.00 ➝ $619.00Low
7/8/2020SunTrust BanksUpgradeHold ➝ Buy$400.00 ➝ $750.00Low
7/1/2020OppenheimerBoost TargetOutperform$625.00 ➝ $675.00High
6/24/2020Credit Suisse GroupBoost TargetOutperform$605.00 ➝ $700.00High
6/12/2020Jefferies Financial GroupBoost TargetBuy$657.00 ➝ $691.00High
6/2/2020Jefferies Financial GroupReiterated RatingBuy$657.00Low
6/2/2020CowenReiterated RatingHold$584.00Low
6/2/2020OppenheimerReiterated RatingBuy$625.00Low
6/2/2020Cantor FitzgeraldBoost TargetNeutral$400.00 ➝ $624.00Low
5/28/2020BarclaysBoost Target$530.00 ➝ $615.00High
5/27/2020CfraLower TargetHold$557.00 ➝ $549.00Low
5/27/2020SVB LeerinkBoost TargetOutperform$622.00 ➝ $625.00High
5/26/2020SVB LeerinkReiterated RatingBuy$622.00Low
5/26/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$559.00 ➝ $734.00High
5/6/2020Robert W. BairdBoost TargetNeutral ➝ Neutral$487.00 ➝ $510.00High
5/6/2020BMO Capital MarketsBoost TargetMarket Perform$466.00 ➝ $525.00High
5/6/2020Royal Bank of CanadaLower Target$533.00 ➝ $524.00Medium
5/6/2020Piper SandlerBoost Target$550.00 ➝ $600.00Low
5/6/2020Morgan StanleyBoost TargetEqual Weight$409.00 ➝ $555.00Medium
5/6/2020OppenheimerBoost TargetOutperform$525.00 ➝ $625.00High
5/6/2020Credit Suisse GroupBoost TargetOutperform$596.00 ➝ $605.00High
5/6/2020The Goldman Sachs GroupBoost TargetConviction-Buy$636.00 ➝ $700.00High
5/6/2020SVB LeerinkBoost TargetOutperform$604.00 ➝ $622.00High
5/1/2020Piper SandlerReiterated RatingOverweightLow
4/28/2020CitigroupDowngradeBuy ➝ Neutral$540.00 ➝ $575.00High
4/19/2020BenchmarkInitiated CoverageHoldLow
4/17/2020BMO Capital MarketsBoost TargetMarket Perform$379.00 ➝ $466.00High
4/17/2020BenchmarkUpgradeHold ➝ Buy$655.00High
4/15/2020Morgan StanleyLower TargetEqual Weight$410.00 ➝ $409.00Medium
4/15/2020JPMorgan Chase & Co.Boost TargetNeutral$375.00 ➝ $429.00Medium
4/8/2020BenchmarkInitiated CoverageHoldMedium
4/7/2020SVB LeerinkBoost TargetOutperform$600.00 ➝ $604.00Medium
4/6/2020Wells Fargo & CompanyBoost TargetEqual Weight$370.00 ➝ $435.00Low
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$455.00High
3/12/2020ArgusBoost TargetBuy$430.00 ➝ $540.00High
3/11/2020OppenheimerBoost TargetOutperform$450.00 ➝ $525.00Medium
3/4/2020CfraBoost TargetBuy ➝ Hold$460.00 ➝ $487.00High
3/4/2020Piper SandlerBoost Target$435.00 ➝ $500.00High
2/28/2020CowenBoost TargetMarket Perform$386.00 ➝ $495.00High
2/28/2020CitigroupBoost TargetBuy$420.00 ➝ $540.00High
2/27/2020BarclaysInitiated CoverageOverweight$530.00High
2/26/2020Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00Medium
2/26/2020Credit Suisse GroupBoost TargetTop Pick ➝ Outperform$420.00 ➝ $510.00High
2/26/2020Robert W. BairdDowngradeOutperform ➝ Neutral$410.00High
2/25/2020Jefferies Financial GroupUpgradeHold ➝ Buy$355.00 ➝ $492.00High
2/24/2020Evercore ISIUpgradeIn-Line ➝ Outperform$500.00High
2/11/2020ArgusUpgradeHold ➝ Buy$430.00Medium
2/7/2020Evercore ISIInitiated CoverageHold$400.00Low
2/7/2020Morgan StanleyLower TargetEqual Weight$411.00 ➝ $410.00Low
2/7/2020SunTrust BanksBoost TargetHold$400.00High
1/22/2020OppenheimerBoost TargetOutperform$430.00 ➝ $450.00Low
1/17/2020Morgan StanleyBoost TargetEqual Weight$387.00 ➝ $411.00Low
1/14/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
12/23/2019Raymond JamesInitiated CoverageMarket PerformN/A
12/13/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
12/9/2019Credit Suisse GroupUpgradeNeutral ➝ Outperform$400.00Low
11/12/2019SunTrust BanksInitiated CoverageHold$360.00Medium
11/11/2019Evercore ISIReiterated RatingBuy$395.00Low
11/6/2019CitigroupUpgradeNeutral ➝ Buy$340.00 ➝ $420.00Low
11/6/2019OppenheimerLower Target$480.00 ➝ $430.00Low
11/6/2019BMO Capital MarketsBoost TargetMarket Perform$344.00 ➝ $358.00Medium
11/6/2019JPMorgan Chase & Co.Reiterated RatingHold$375.00Medium
11/6/2019Credit Suisse GroupBoost TargetNeutral ➝ Neutral$310.00 ➝ $340.00Medium
10/16/2019Bank of AmericaInitiated CoverageNeutral$325.00Low
10/8/2019CowenSet TargetHold$349.00Low
10/8/2019Piper Jaffray CompaniesSet TargetBuy$435.00Low
10/8/2019BMO Capital MarketsSet TargetHold$344.00Low
9/23/2019GuggenheimUpgradeNeutral ➝ Buy$355.00 ➝ $403.00Low
8/7/2019Robert W. BairdUpgradeNeutral ➝ Outperform$410.00Low
8/7/2019Credit Suisse GroupLower TargetNeutral$333.00 ➝ $325.00Low
8/7/2019BMO Capital MarketsLower TargetMarket Perform$344.00Low
7/29/2019CowenReiterated RatingHold$353.00Medium
6/21/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
6/18/2019ArgusDowngradeBuy ➝ HoldHigh
6/14/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
6/11/2019SVB LeerinkSet TargetBuy$453.00Low
5/23/2019CitigroupLower TargetNeutral ➝ Neutral$396.00 ➝ $340.00Low
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$336.00High
5/13/2019Cantor FitzgeraldLower TargetNeutral$441.00 ➝ $405.00Medium
5/8/2019BMO Capital MarketsLower TargetPositive ➝ Market Perform$412.00 ➝ $375.00Medium
5/8/2019Morgan StanleyLower TargetEqual Weight$420.00 ➝ $389.00Medium
5/8/2019UBS GroupLower TargetBuy$480.00 ➝ $440.00Medium
5/7/2019Piper Jaffray CompaniesReiterated RatingOverweight$435.00Medium
5/7/2019CowenReiterated RatingHold$353.00Medium
4/17/2019Jefferies Financial GroupLower TargetHold$376.00 ➝ $343.00High
2/26/2019Piper Jaffray CompaniesBoost TargetOverweight$487.00Medium
2/22/2019GuggenheimDowngradeBuy ➝ Neutral$466.00 ➝ $425.00Low
2/7/2019OppenheimerBoost TargetOutperform$440.00 ➝ $480.00Low
2/7/2019BMO Capital MarketsBoost TargetMarket Perform$412.00Low
2/6/2019Cantor FitzgeraldReiterated RatingHold$441.00High
1/7/2019CowenReiterated RatingHold$385.00Low
1/4/2019GuggenheimUpgradeNeutral ➝ Buy$461.00High
12/13/2018The Goldman Sachs GroupUpgradeNeutral ➝ Conviction-BuyLow
12/7/2018SVB LeerinkSet TargetBuy$473.00 ➝ $483.00Low
12/2/2018OppenheimerSet TargetBuy$440.00High
11/13/2018ArgusReiterated RatingBuyLow
11/7/2018JPMorgan Chase & Co.Set TargetHold$405.00Medium
11/6/2018CowenReiterated RatingHold$385.00Medium
10/22/2018CowenReiterated RatingHold$385.00Medium
10/22/2018Cantor FitzgeraldBoost TargetNeutral$441.00Low
10/22/2018JPMorgan Chase & Co.Set TargetHold$405.00Low
10/11/2018Morgan StanleyBoost TargetEqual Weight$409.00 ➝ $412.00High
10/2/2018JPMorgan Chase & Co.Reiterated RatingHoldMedium
10/1/2018SVB LeerinkBoost TargetOutperform$506.00 ➝ $512.00High
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$415.00High
8/16/2018CowenReiterated RatingHold$385.00Low
8/6/2018BarclaysBoost TargetUnderweight ➝ Underweight$290.00 ➝ $305.00Low
8/3/2018SunTrust BanksReiterated RatingHold$400.00Low
8/3/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$396.00 ➝ $409.00Low
8/3/2018Robert W. BairdDowngradeOutperform ➝ NeutralLow
8/2/2018BMO Capital MarketsSet TargetHold$388.00Low
7/24/2018Jefferies Financial GroupReiterated RatingHold$340.00Medium
7/16/2018ArgusBoost TargetBuy ➝ Buy$383.00 ➝ $415.00Low
7/13/2018Morgan StanleyBoost TargetEqual Weight$370.00 ➝ $396.00Low
7/2/2018SunTrust BanksSet TargetHold$344.00Low
6/27/2018OppenheimerUpgradeMarket Perform ➝ Outperform$325.00High
6/27/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
5/23/2018BarclaysSet TargetSell$290.00Low
5/7/2018Royal Bank of CanadaLower TargetSector Perform$342.00Low
5/5/2018Credit Suisse GroupSet TargetBuy$420.00Low
5/4/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$400.00 ➝ $370.00Low
5/4/2018SVB LeerinkSet TargetBuy$502.00 ➝ $435.00Low
5/4/2018BMO Capital MarketsSet TargetMarket Perform ➝ Hold$398.00 ➝ $361.00Low
5/4/2018CowenReiterated RatingOutperform$400.00 ➝ $350.00Low
5/4/2018SunTrust BanksLower TargetHold$344.00Low
5/3/2018BarclaysSet TargetSell$290.00Low
5/1/2018GuggenheimDowngradeBuy ➝ NeutralLow
4/27/2018Credit Suisse GroupSet TargetBuy$420.00High
4/27/2018CowenReiterated RatingHold$400.00Low
4/17/2018Credit Suisse GroupLower TargetBuy$440.00 ➝ $420.00Low
4/9/2018Raymond JamesReiterated RatingOutperform ➝ Market PerformLow
4/9/2018UBS GroupDowngradeOutperform ➝ Market PerformLow
3/13/2018BTIG ResearchReiterated RatingHoldMedium
3/13/2018Deutsche Bank AktiengesellschaftSet TargetHold$367.00Medium
2/13/2018BTIG ResearchReiterated RatingHoldHigh
2/9/2018SunTrust BanksSet TargetHold$430.00Low
2/9/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$401.00 ➝ $415.00High
2/9/2018SVB LeerinkLower TargetOutperform ➝ Outperform$568.00 ➝ $502.00High
2/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHigh
2/9/2018GuggenheimSet TargetBuy$530.00High
2/8/2018Jefferies Financial GroupReiterated RatingNeutral ➝ Hold$380.00High
2/8/2018BTIG ResearchDowngradeBuy ➝ Neutral$480.00High
2/8/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$398.00 ➝ $444.00Low
2/7/2018Credit Suisse GroupSet TargetBuy$440.00High
2/7/2018CowenReiterated RatingHold$450.00High
2/2/2018Jefferies Financial GroupReiterated RatingHold$421.00Medium
1/24/2018JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$455.00 ➝ $457.00Low
1/9/2018CitigroupReiterated RatingNeutral ➝ Neutral$380.00 ➝ $388.00High
12/28/2017ArgusLower TargetPositive ➝ Buy$540.00 ➝ $470.00Low
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00Low
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$397.00Medium
12/1/2017CitigroupDowngradeBuy ➝ Neutral$480.00 ➝ $380.00High
11/28/2017JPMorgan Chase & Co.Reiterated RatingHoldMedium
11/28/2017BTIG ResearchLower TargetBuy ➝ Buy$520.00 ➝ $480.00Low
11/27/2017BMO Capital MarketsSet TargetHold$444.00High
11/22/2017BTIG ResearchReiterated RatingBuy$520.00Low
11/16/2017Evercore ISILower TargetOutperform$605.00 ➝ $445.00N/A
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/A
11/9/2017Morgan StanleyLower TargetEqual Weight$490.00 ➝ $463.00N/A
11/9/2017Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$473.00 ➝ $425.00N/A
11/9/2017BMO Capital MarketsLower TargetMarket Perform$491.00 ➝ $479.00N/A
11/9/2017CitigroupReiterated RatingBuy$480.00N/A
11/3/2017Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
10/31/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$540.00N/A
10/20/2017BarclaysDowngradeEqual Weight ➝ Underweight$450.00 ➝ $395.00N/A
10/16/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$450.00 ➝ $490.00N/A
10/6/2017Jefferies Financial GroupReiterated RatingHold$471.00 ➝ $500.00N/A
10/2/2017SunTrust BanksReiterated RatingHold$435.00Medium
(Data available from 10/1/2017 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 42 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
3/5/2022
  • 5 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 4 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/4/2022
  • 8 very positive mentions
  • 49 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
6/3/2022
  • 4 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/3/2022
  • 9 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/2/2022
  • 5 very positive mentions
  • 38 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
9/1/2022
  • 19 very positive mentions
  • 34 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
10/1/2022

Current Sentiment

  • 19 very positive mentions
  • 34 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Regeneron Pharmaceuticals logo
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Read More

Today's Range

Now: $688.87
Low: $685.97
High: $702.38

50 Day Range

MA: $637.14
Low: $573.97
High: $724.32

52 Week Range

Now: $688.87
Low: $538.01
High: $754.67

Volume

800,892 shs

Average Volume

973,986 shs

Market Capitalization

$75.09 billion

P/E Ratio

13.75

Dividend Yield

N/A

Beta

0.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Regeneron Pharmaceuticals?

The following equities research analysts have issued stock ratings on Regeneron Pharmaceuticals in the last year: Argus, Bank of America Co., Barclays PLC, Benchmark Co., BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Sanford C. Bernstein, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for REGN.

What is the current price target for Regeneron Pharmaceuticals?

21 Wall Street analysts have set twelve-month price targets for Regeneron Pharmaceuticals in the last year. Their average twelve-month price target is $746.33, suggesting a possible upside of 8.3%. Guggenheim has the highest price target set, predicting REGN will reach $925.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $575.00 for Regeneron Pharmaceuticals in the next year.
View the latest price targets for REGN.

What is the current consensus analyst rating for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals currently has 1 sell rating, 6 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REGN will outperform the market and that investors should add to their positions of Regeneron Pharmaceuticals.
View the latest ratings for REGN.

What other companies compete with Regeneron Pharmaceuticals?

Other companies that are similar to Regeneron Pharmaceuticals include Vertex Pharmaceuticals, Alnylam Pharmaceuticals, Zoetis, GSK and Sanofi. Learn More about companies similar to Regeneron Pharmaceuticals.

How do I contact Regeneron Pharmaceuticals' investor relations team?

Regeneron Pharmaceuticals' physical mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company's listed phone number is (914) 847-7000 and its investor relations email address is [email protected] The official website for Regeneron Pharmaceuticals is www.regeneron.com. Learn More about contacing Regeneron Pharmaceuticals investor relations.